Amgen, bone mineral density

Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.
Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
MarketWatch1d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday ...
Benzinga.com1d
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Hosted on MSN1d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Yahoo1d
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone ...